Y Intercept Hong Kong Ltd Increases Stock Holdings in Inspire Medical Systems, Inc. $INSP

Y Intercept Hong Kong Ltd increased its stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 124.1% during the 1st quarter, HoldingsChannel.com reports. The firm owned 158,274 shares of the company’s stock after purchasing an additional 87,639 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Inspire Medical Systems were worth $8,164,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of INSP. Wellington Management Group LLP bought a new stake in Inspire Medical Systems in the fourth quarter worth $203,929,000. Wasatch Advisors LP increased its position in Inspire Medical Systems by 7.2% during the second quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock valued at $212,095,000 after acquiring an additional 110,288 shares during the last quarter. Morgan Stanley increased its position in Inspire Medical Systems by 179.5% during the fourth quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock valued at $116,188,000 after acquiring an additional 809,121 shares during the last quarter. Deerfield Management Company L.P. increased its position in Inspire Medical Systems by 648.4% during the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock valued at $77,739,000 after acquiring an additional 907,694 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Inspire Medical Systems by 2.3% in the second quarter. State Street Corp now owns 1,030,902 shares of the company’s stock valued at $133,780,000 after acquiring an additional 22,843 shares during the period. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Analyst Upgrades and Downgrades

INSP has been the subject of a number of recent analyst reports. Freedom Capital raised shares of Inspire Medical Systems to a “strong-buy” rating in a research note on Tuesday. Weiss Ratings lowered shares of Inspire Medical Systems from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, May 6th. Zacks Research lowered shares of Inspire Medical Systems from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 13th. Piper Sandler downgraded shares of Inspire Medical Systems from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $85.00 to $55.00 in a research note on Tuesday, May 5th. Finally, Mizuho dropped their target price on Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating for the company in a research report on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $81.05.

Inspire Medical Systems Trading Up 0.0%

NYSE:INSP opened at $46.95 on Friday. Inspire Medical Systems, Inc. has a twelve month low of $38.91 and a twelve month high of $147.03. The company has a market cap of $1.35 billion, a price-to-earnings ratio of 10.46, a price-to-earnings-growth ratio of 4.75 and a beta of 0.71. The stock has a fifty day simple moving average of $44.57 and a 200-day simple moving average of $62.43.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Monday, May 4th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.38. The firm had revenue of $204.58 million for the quarter, compared to analysts’ expectations of $200.04 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The business’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.10 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, equities research analysts predict that Inspire Medical Systems, Inc. will post 0.93 EPS for the current fiscal year.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.